TABLE 2.
Clinic Visits*, Epidemiologic Treatment†, Tested‡, and Overtreatment§ for Contact Visits for Gonorrhea and/or Chlamydia, Public Health Seattle/King County STD Clinic, 1994 to 2018
| 1994–1998 | 1999–2003 | 2004–2008 | 2009–2013 | 2014–2018 | Total | |
|---|---|---|---|---|---|---|
| n (%) | ||||||
| Total | ||||||
| Contact to GC and/or CT visits¶ | 949 (1) | 1082 (2) | 1343 (2) | 2353 (4) | 3159 (6) | 8886 (3) |
| Epidemiologically treated¶ | 843 (89) | 981 (91) | 1208 (90) | 2084 (89) | 2744 (87) | 7860 (89) |
| Tested for GC and/or CT¶ | 776 (92) | 922 (94) | 1119 (93) | 1963 (94) | 2637 (96) | 7417 (94) |
| GC and/or CT positive¶ | 154 (20) | 258 (28) | 341 (31) | 638 (33) | 897 (34) | 2288 (31) |
| Overtreated for GC and/or CT¶ | 622 (74) | 664 (72) | 778 (58) | 1325 (67) | 1740 (66) | 5129 (65) |
| MSM | ||||||
| Contact to GC and/or CT visits¶ | 256 (4) | 374 (4) | 670 (4) | 1685 (8) | 2538 (10) | 5523 (7) |
| Epidemiologically treated¶ | 236 (92) | 349 (93) | 609 (91) | 1523 (90) | 2234 (88) | 4951 (90) |
| Tested for GC and/or CT | 232 (98) | 335 (96) | 583 (96) | 1463 (96) | 2185 (98) | 4789 (97) |
| Urethral¶ | 202 (87) | 319 (95) | 568 (97) | 1370 (94) | 1792 (82) | 4251 (89) |
| Rectal¶ | 126 (54) | 226 (67) | 402 (69) | 1081 (74) | 1630 (75) | 3465 (72) |
| Pharyngeal¶ | 187 (81) | 296 (88) | 541 (93) | 1389 (95) | 2059 (94) | 4472 (93) |
| Urethral, rectal, and pharyngeal | 159 (69) | 281 (84) | 527 (90) | 1300 (89) | 1689 (77) | 4798 (82) |
| GC and/or CT positive | 60 (26) | 104 (31) | 193 (33) | 522 (36) | 757 (35) | 1636 (34) |
| Urethral | 11 (5) | 20 (6) | 26 (5) | 80 (6) | 119 (7) | 256 (6) |
| Rectal | 38 (30) | 73 (32) | 128 (32) | 358 (33) | 491 (30) | 1088 (31) |
| Pharyngeal¶ | 23 (12) | 31 (10) | 66 (12) | 239 (17) | 355 (17) | 714 (16) |
| Overtreated for GC and/or CT¶ | 172 (74) | 231 (69) | 390 (67) | 941 (64) | 1428 (65) | 3162 (66) |
| MSW | ||||||
| Contact to GC and/or CT visits¶ | 623 (1) | 598 (2) | 526 (2) | 515 (2) | 475 (3) | 2737 (2) |
| Epidemiologically treated¶ | 550 (88) | 530 (89) | 467 (89) | 439 (85) | 399 (84) | 2385 (87) |
| Tested for urogenital GC and/or CT¶ | 511 (93) | 515 (97) | 426 (91) | 381 (87) | 346 (87) | 2179 (92) |
| GC and/or CT positive¶ | 79 (15) | 122 (24) | 102 (24) | 70 (18) | 92 (26) | 465 (21) |
| Overtreated for GC and/or CT¶ | 432 (85) | 392 (76) | 321 (75) | 318 (82) | 257 (73) | 1720 (78) |
| Women | ||||||
| Contact to GC and/or CT visits¶ | 70 (<1) | 110 (<1) | 147 (1) | 153 (1) | 146 (2) | 626 (1) |
| Epidemiologically treated¶ | 57 (81) | 102 (93) | 132 (90) | 122 (80) | 111 (76) | 524 (84) |
| Tested for urogenital GC and/or CT¶ | 32 (56) | 72 (71) | 110 (83) | 109 (89) | 96 (86) | 419 (80) |
| GC and/or CT positive | 14 (44) | 31 (43) | 43 (39) | 43 (39) | 41 (43) | 172 (41) |
| Overtreated for GC and/or CT | 18 (56) | 41 (57) | 67 (61) | 66 (61) | 55 (57) | 247 (59) |
*
Of all clinic visits.
†
Of asymptomatic patients deemed a contact to GC and/or CT.
‡
Of those receiving epidemiologic treatment.
§
Of those tested.
¶
Test for trend significant at the P < 0.05 level.